Subsequent Course Of Rituxan® Improved Outcomes In Rheumatoid Arthritis Patients Who Inadequately Responded To Tnf Antagonist Therapy

Thu, 23 Nov 2006 02:00 PM EST

... Genentech, Inc. (NYSE: DNA) and Biogen Idec, Inc. (Nasdaq: BIIB) today announced positive results from interim analyses of ongoing open-label extension studies of Rituxan® (Rituximab) therapy in patients with rheumatoid arthritis (RA) who have had an inadequate response to previous treatment with one or more tumor necrosis factor (TNF) antagonist therapies. [click link for full article] ...